Press Releases Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse Other stock markets 04:00:02 2024-05-24 pm EDT			5-day change	1st Jan Change
7.29 ^USD	+2.97%		-12.27%	-61.02%

May. 10	Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annovis Announces New Publication in a Peer-Reviewed Journal	May. 21	GL
Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	May. 17	BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	May. 16	BU
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	May. 16	BU
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results	May. 13	GL
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease	May. 09	GL
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease	May. 09	AQ
Annovis Bio : Regulation FD Presentation - Form 8-K	May. 06	PU
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders	May. 06	GL
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	Apr. 29	GL
Annovis Bio : Material Agreement - Form 8-K	Apr. 26	PU
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 02	GL
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	Apr. 01	GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	AQ
Annovis Bio : Material Event - Form 8-K	Mar. 20	PU
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	GL
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	AQ
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	Feb. 15	AQ
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Feb. 14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Press Releases

Filters